As an immunosuppressive and anti-inflammatory cytokine, IL-10 was recently reported to play roles in CCR5 expression in human monocytes. CCR5 promoter regions contain Oct-2, TCF-1a a, GATA, and STAT binding sites. Here, we studied the signals involved in the CCR5 expression in IL 
Chemokines can be grouped in two main subfamilies, defined as CXC and CC, and other minor families such as c/lymphotactin and CX3C/fractalkine. 1) Inflammatory cytokines such as IL-1, 6, and TNF-a are potent inducers of various chemokine production. In contrast, IL-10 inhibits chemokine production and has an immunosuppressive and thus an anti-inflammatory effect.
2) Chemokines bind to and activate seven-transmembrane domain receptors. To date, six receptors for the CXC chemokines, CXCR1-6, and ten for CC chemokines, CCR1-10, have been identified.
3) Among them, CCR5 was particularly of interest, since it has been shown to act as entry/fusion cofactors for HIV infection, thus CCR5 mutation is associated with a relative resistance to HIV infection. In this context, we studied the regulation of the signal pathway leading to CCR5 gene expression by IL-10, using a phorbol 12-O-tetradecanoyl 13-myrystrate acetate (PMA)-differentiated HL-60 cell line. While CCR5 in human monocytes are upregulated by IL-10, 4) therefore permitting efficient HIV infection, no intimate signal pathway has been explored.
IL-10 was originally identified as a soluble factor produced by CD4 ϩ , Th2-type T cell clones that inhibit the production of Th1 cytokine by T cells. 5) Although IL-10 is a potent inhibitor of monocyte/macrophage activation, it also has numerous immunostimulatory effects and activates a diverse array of functional responses in monocytes. 6) We are interested in the regulation of CCR5 expression by IL-10, since this could be a promising way to target the regulation of HIV receptors, providing evidence that IL-10 could be implicated in controlling inflammatory processes through the modulation of chemokine receptor expression.
Functional IL-10R complexes are tetramers consisting of two IL-10Rs, 1 and 2. Binding of IL-10 to the extracellular domain of IL-10R1 activates phosphorylation of the receptor-associated kinases, JAK1 and Tyk2. [7] [8] [9] These kinases then phosphorylate specific tyrosine (Tyr) residues of IL-10R1, resulting in the recruitment of STAT-3. STAT-3 binds to the phosphorylated-Tyr of IL-10R1 via the SH2 domain, and is phosphorylated at Tyr705 and serine (Ser) 727. Tyr705 is phosphorylated by JAK1, and Ser727 is phosphorylated by the H7-sensitive pathway or PD98059-sensitive pathway. Then, STAT-3 homodimerizes and translocates to the nucleus, where it binds to STAT-binding elements in the promoter of IL-10 responsive genes. Previous reports show that both phosphorylations, or only Tyr phosphorylation, is required for the full transcriptional activity of STAT-3, being dependent on the cell type and the stimulus used. 10, 11) It has also been reported that the minimal promoter region of CCR5 gene has a 417-nt region, as shown in Fig. 1 , which contains the binding site, Oct-2, TCF-1a, GATA and STAT. [12] [13] [14] We attempted, in this study, to reveal whether IL-10 activates Erk1/2 and STAT3 to induce CCR5 upregulation in the PMA-differentiated HL-60 cell line. Electrophoresis and Immunoblotting For the preparation of cell lysate, 1ϫ10 6 packed cells were lysed with lysis buffer as described elsewhere. 15) An equal volume of 2ϫLaemmli sample buffer was added to each cell lysate. Each sample was boiled for 5 min, and equal amounts of protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Afterwards, they were transferred to nitrocellulose membranes, blocked with 3% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for 1h and then incubated with primary Ab for 1 h at room temperature. After incubation with the secondary Ab coupled to horseradish peroxidase, detection was achieved using the enhanced chemiluminescence system.
Interleukin

MATERIALS AND METHODS
Cells and Reagents
Immunoprecipitation Cell lysate (1 ml) was prepared from 5ϫ10 6 cells, as described previously. 15) A 20 ml portion of protein A Sepharose (Sigma, MO, U.S.A.) and 2 mg Ab were added to each supernatant, followed by incubation overnight at 4°C. The precipitates were spun down, washed three times with lysis buffer, and were then boiled for 5 min in Laemmli sample buffer in the case of immunoblotting.
Flow Cytometry Since macrophage-like HL-60 cells loosely adhered onto the plastic dishes, the cells were detached by a cell scraper (Assist, Tokyo) and dispersed in PBS by pipetting. Cell staining was performed using anti-CCR5 MAb (2D7, PharMingen) for 30 min at 4°C, followed by FITC-conjugated rabbit anti-mouse secondary Ab (DAKO, Denmark) for 30 min at 4°C, then the cells were analyzed by a fluorescence-activated cell sorter (FACS) Calibur using a CELLQuest program (Becton Dickinson, CA, U.S.A.).
RT-PCR RNA was prepared using an RNA purification kit (Qiagen, Tokyo). RT-PCR was performed as recommended by the supplier (Takara Shuzo, Shiga) using oligo(dT) 30 primer and total RNA (1 mg) for first strand cDNA synthesis. Primer sequences were as follows: CCR5 sense, 5Ј-TGCTTGGCCAAAAAGAGAGT-3Ј; antisense, 5Ј-GACCAGCCCCCAAGATGACTA-3Ј. PCR was performed at an annealing temperature of 60°C and for 30 amplification cycles. In the case of GAPDH (sense, 5Ј-CCACCCATG-GCAAATTCCATGGCA; antisense, 5Ј-TCTAGACGGCA-GGTCAGGTCAGGTCCACC), PCR was performed at an annealing temperature of 55°C and for 25 cycles.
Nuclear Extract Preparation and Electrophoresis Mobility Shift Assay (EMSA) Nuclear extracts from cells were prepared as described previously. 16) An oligonucleotide containing a STAT binding element (5Ј-ACCCTC-CTTCAAAAGAAACAGCATTT-3Ј) was end-labeled with [g-32 P]ATP by T4 polynucleotide kinase. The labeled oligonucleotide probes (ca. 300000 cpm, 0.1 pmol) were mixed with 2 mg of poly(dI-dC)/poly(dI-dC) and 4 mg of nuclear extract proteins in a final volume of 20 ml of solution, as described previously. The reaction mixture was incubated at room temperature for 30 min and electrophoresed as described previously 16) and gels were dried and analyzed by BAS2000 (Fuji Film, Tokyo).
Transfection and Reporter Gene Assays Transient DNA transfections were performed according to the Fugene reagent. Fugene/DNA complexes were prepared according to the manufacturer's instruction. Each dish received pGL-CCR5 (Ϫ416-ϩ61) (provided by H. Moriuchi, Nagasaki University), 0.1 mg of pRL-TK control plasmid, 1 mg of c-Jun and/or c-Fos, and/or STAT-3 expression plasmid, pRSV-c-Jun and pRSV-c-Fos 17) (provided by Dr. H. Iba, The University of Tokyo, Tokyo, and Dr. T. Curran, St. Jude Children's Research Hospital, Memphis, TN, U.S.A.), and pEF-BOS-STAT-3 18) (provided by Dr. S. Akira, Osaka University, Osaka). The PMA-differentiated HL-60 or HEK293 cells were exposed to the Fugene/DNA complex for 16 h, and then stimulated with IL-10. After 6 h, luciferase activities were assayed by the Lumat LB9501 (Bertold Japan, Tokyo). An empty plasmid (pRSV and/or pEF-BOS) was used to normalize the total amount of DNA in each transfection. The efficiency of transfection was standardized with sea pansy luciferase activity (Promega, Madison, WI, U.S.A.).
RESULTS
Effects of IL-10 on CCR5 Protein Expression
To investigate whether CCR5 protein was upregulated by IL-10, flow cytometer studies were performed using the CCR5 MAb (2D7). The HL-60 cell line was differentiated with 10 nM PMA for 72 h. As shown in Fig. 2A , differentiated HL-60 showed a moderate increased expression of CCR5 compared to undifferentiated HL-60 cells. Differentiated HL-60 cells treated with 20 ng/ml of IL-10 for an additional 24 h exhibited a marked increase in CCR5 protein compared to IL-10 untreated differentiated HL-60 cells. This increase was inhibited significantly by PD98059 (10 mM), a MEK inhibitor (Fig.  2B) .
Effects of IL-10 on CCR5 mRNA Expression To investigate whether CCR5 mRNA was upregulated by IL-10, RT-PCR was performed using specific primers. As shown in Fig. 3 , PMA-differentiated HL-60 showed a moderate increased expression of CCR5 mRNA compared to HL-60 cells. CCR5 mRNA was increased further by the IL-10-treatment compared to untreated differentiated HL-60 cells. This increase was inhibited significantly by PD98059 (10 mM), nullifying the IL-10 treatment.
Activation of Erk1/2 in Differentiated HL-60 Cells by IL-10 As shown above, an MEK inhibitor, PD98059, downregulated the CCR5 expression both at the protein and mRNA levels. Therefore, we tested the possibility that IL-10 activates ERK1/2 in PMA-differentiated cells. PMA-differentiated cells were stimulated with IL-10 for 30 min, and the activation of Erk1/2 was assessed by blotting whole cell lysates with anti-phospho-Erk1/2 MAb. Figure 3B shows that PMA increased a minimal amount of phosphorylated Erk1/2, and the addition of IL-10 markedly enhanced phosphorylated Erk1/2. The activation of Erk1 and 5 were not stained with anti-PY MAb (data not shown), only the immunoprecipitate by anti-STAT-3 was positively stained with anti-PY MAb (Fig. 4B) , assuming that p90-92 Tyr-phosphorylated protein is STAT-3. Further, we examined the effect of PD98059 on Tyr phosphorylation and Ser phosphorylation of STAT-3. As shown in Fig. 4C , PD98059 (10 mM) did not abrogate the Tyr phosphorylation of STAT-3 (Fig. 4C) . In contrast, a Ser-727 phosphorylation band of STAT-3 was observed in differentiated HL-60 cells and further enhanced by the stimulation with IL-10. Ser-727 phosphorylation was mostly diminished by the addition of PD98059.
Induction of STAT-3 Binding Complexes
To investigate whether the activation of STAT-3 results in increased DNA binding activity, EMSA were performed with a radiolabeled DNA probe containing the STAT-3 site using nuclear extracts. Figure 5 shows that significant DNA binding activity of STAT-3 is detectable in nuclear extracts of IL-10-treated PMA-differentiated HL-60 cells. The specificity of the STAT-3 complex was confirmed in competition experiments by adding 100-fold excess of an unlabeled probe. Furthermore, PD98059 completely inhibited STAT-3 DNA binding activity. These results indicate that the IL-10-stimulated increase in Ser phosphorylation of STAT-3 corresponds with the increase in DNA binding. Treatment with PD98059 blocked the IL-10-stimulated serine phosphorylation and reduced STAT-3 DNA binding activity.
Involvement of STAT-3 in the Potentiation of IL-10-Induced CCR5 Expression in PMA-Differentiated HL-60
Cells To confirm the possibility that STAT-3 can potentiate IL-10-induced CCR5 expression, we carried out a reporter gene assay. First, DNA constructs (CCR5-luc) containing CCR5-promoter (Ϫ416-ϩ61) inserted in front of the luciferase reporter gene were transfected into macrophage-like HL-60, and stimulated IL-10 with or without STAT-3 expression plasmid. The transcriptional activity was determined in a dual-luciferase reporter assay system. However, the luciferase activity was low because the transfection efficiency was too low (data not shown). Therefore, we used HEK293T cells because of their high transfection efficiency and endogenous expression of IL-10R, STAT-3, which are necessary for CCR5 expression. The protein expression by transfected expression plasmid was detected by Western blot. It should be noted that the expression of CCR5 was induced by the transfection of STAT-3 and/or Fos and/or Jun (Fig. 6A) . Next, 293T cells were transfected with STAT-3 expression plasmid and CCR5-luc reporter gene plasmid. The introduction of STAT-3 enhanced the CCR5-luc transcriptional activity, as shown in Fig. 6B . The expression of STAT-3 and c-Jun induced a moderate increase in CCR5 transcription in response to IL-10. Stimultaneous transfection of STAT-3, cFos, and c-Jun induced enhanced CCR5 transcription, which was further augmented by IL-10. It should be noted that transfection efficiency was 90-fold as efficient in HEK293T cells when compared with macrophage-like HL-60 cells. DISCUSSION CCR5, the CC chemokine receptor, is preferentially expressed in type 1 T helper cells, and serves as a receptor for RANTES, MIP-1a.
1) CCR5 is also essential for the cellular entry of macrophage-tropic (R5) human immunodeficiency virus type 1 (HIV-1), and levels of its expression appear to be critical for infectivity by R5 HIV-1. [19] [20] [21] Moriuchi et al. have cloned and characterized the promoter region of CCR5 and identified several transcription factors, TCF1a, Oct and GATA. 13) Here, we have demonstrated that IL-10 induces the CCR5 expression in PMA-differentiated HL-60 cells, which is then inhibited by the MEK inhibitor, PD98059.
PMA has been used to induce the differentiation of HL-60 cells. PMA inhibits cell proliferation and promotes cell adhesion, spreading, and phagocytic activity, exhibiting all characteristics of macrophage-like cells. 22) In this study, almost 90% of cultured HL-60 cells became adherent to the surface after 72 h incubation with 10 nM PMA. PMA activates PKCa, b, d and/or phosphatydylinositol-3-OH-kinase (PI3- kinase) 23) and/or the MEK/ERK signaling pathway. These signal transductions might be involved in increasing the basal expression of IL-10R. Actually, we have shown here that STAT-3 Tyr and Ser phosphorylation were both increased by the stimulation of IL-10. Since PD98059 inhibited STAT-3 Ser phosphorylation, Erk is presumed to be involved in the effect of IL-10. As expected, we observed increased Erk1/2 phosphorylation. When we inhibited STAT-3 Ser phosphorylation with PD98059, we found that STAT-3 Tyr phosphorylation was unaffected. These results suggest that Tyr phosphorylation by IL-10 is independent of the Ser phosphorylation. In addition, we found that IL-10 increased DNA binding of STAT-3, and that PD98059 reduced this DNA binding, as well as STAT-3 Ser phosphorylation. From these results, we concluded that STAT-3 Ser 727 phosphorylation is required for full transcriptional activity of STAT-3 by the stimulation of IL-10.
Recently, it has been determined that STAT-3 can directly associate with c-Jun and participate in cooperative transcriptional activation of the a2-macroglobulin enhancer, which contains both STAT-3 and an AP-1 response elements. 24) Also, AP-1 can directly associate with a number of transcription factors in the absence of AP-1 binding site. 25) As we could not detect any AP-1 response element in the CCR5 promoter, we hypothesized that c-Jun and c-Fos associate with STAT-3 without directly binding to the DNA. Overexpression of c-Fos and/or c-Jun and/or STAT-3 enhanced CCR5-luciferase reporter gene transcription. These indicate that IL-10 induces STAT-3/3 homodimerization and translocation to the nucleus, followed by STAT-3-c-Jun and/or c-Fos association and DNA binding. C-Fos and c-Jun might thus enhance transcriptional activation by association with STAT-3. Treatment of macrophages with IL-10, granulocytemacrophage colony-stimulating factor, or macrophage colony-stimulating factor upregulate CCR5 expression. 26) In human monocytes, IL-10 is reported to upregulate CCR5 expression by prolonging the mRNA half-life. 4) Several transcription factors have been demonstrated to regulate CCR5 expression, including TCF1a, GATA-1, and Oct-2. 9) In this study, we first demonstrated that STAT-3, cFos, and c-Jun can up-regulate CCR5 expression by IL-10 stimulation. Furthermore, we first indicated that Erk-mediated phosphorylation of Ser is required for full stimulation of STAT-3, and for the CCR5 expression by IL-10 stimulation.
IL-10 acts on antigen-presenting cells to inhibit the expression of major histocompatibility complex class II and B7, as well as cytokine (IFN-g, IL-2), production that are necessary for T cell activation. 27, 28) Inhibition of the expression of these genes is in part due to the rapid expression of suppressors of cytokine signaling-3 (SOCS-3) by IL-10. 29) CCR5 is suggested as a target because people who lack a part of the CCR5 gene (CCR5 D32 homozygotes) are resistant to HIV infection but are otherwise apparently normal. [30] [31] [32] [33] Thus, the inhibition of CCR5 expression could be linked to the inhibition of HIV infection. Thus, in addition to the inhibition of a ligand-target interaction, the inhibition of signal transduction leading to the CCR5 expression, i.e., MAP kinase inhibitor, would be a candidate for the regulation of HIV infectivity.
